Literature DB >> 11999007

European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group.

J F Broekmans1, G B Migliori, H L Rieder, J Lees, P Ruutu, R Loddenkemper, M C Raviglione.   

Abstract

As countries approach the elimination phase of tuberculosis, specific problems and challenges emerge, due to the steadily declining incidence in the native population, the gradually increasing importance of the importation of latent tuberculosis infection and tuberculosis from other countries and the emergence of groups at particularly high risk of tuberculosis. Therefore, a Working Group of the World Health Organization (WHO), the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Royal Netherlands Tuberculosis Association (KNCV) have developed a new framework for low incidence countries based on concepts and definitions consistent with those of previous recommendations from WHO/IUATLD Working Groups. In low-incidence countries, a broader spectrum of interventions is available and feasible, including: 1) a general approach to tuberculosis which ensures rapid detection and treatment of all the cases and prevention of unnecessary deaths; 2) an overall control strategy aimed at reducing the incidence of tuberculosis infection (risk-group management and prevention of transmission of infection in institutional settings) and 3) a tuberculosis elimination strategy aimed at reducing the prevalence of tuberculosis infection (outbreak management and provision of preventive therapy for specified groups and individuals). Government and private sector commitment towards elimination, effective case detection among symptomatic individuals together with active case finding in special groups, standard treatment of disease and infection, access to tuberculosis diagnostic and treatment services, prevention (e.g. through screening and bacille Calmette-Guéria immunization in specified groups), surveillance and treatment outcome monitoring are prerequisites to implementing the policy package recommended in this new framework document.

Entities:  

Mesh:

Year:  2002        PMID: 11999007     DOI: 10.1183/09031936.02.00261402

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  61 in total

1.  Continued low rates of transmission of Mycobacterium tuberculosis in Norway.

Authors:  Ulf R Dahle; Per Sandven; Einar Heldal; Dominique A Caugant
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

2.  Tuberculosis elimination in Canada: Truce or victory?

Authors:  Richard Long; Edward Ellis
Journal:  CMAJ       Date:  2015-09-28       Impact factor: 8.262

Review 3.  Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis.

Authors:  Karen R Steingart; Nandini Dendukuri; Megan Henry; Ian Schiller; Payam Nahid; Philip C Hopewell; Andrew Ramsay; Madhukar Pai; Suman Laal
Journal:  Clin Vaccine Immunol       Date:  2008-12-03

4.  Complete republication: Epidemiology of tuberculosis in the EU/EEA in 2010 - Monitoring the progress towards tuberculosis elimination.

Authors:  A Sandgren; V Hollo; E Huitric; C Ködmön
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-12-11

5.  Transmission classification model to determine place and time of infection of tuberculosis cases in an urban area.

Authors:  G de Vries; H W M Baars; M M G G Sebek; N A H van Hest; J H Richardus
Journal:  J Clin Microbiol       Date:  2008-10-08       Impact factor: 5.948

6.  Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection.

Authors:  Homayoun Shams; Stephen E Weis; Peter Klucar; Ajit Lalvani; Patrick K Moonan; Janice M Pogoda; Katie Ewer; Peter F Barnes
Journal:  Am J Respir Crit Care Med       Date:  2005-08-04       Impact factor: 21.405

7.  Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.

Authors:  Sandirai Musuka; Shashikant Srivastava; Chandima Wasana Siyambalapitiyage Dona; Claudia Meek; Richard Leff; Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

8.  Treatment outcome of extra-pulmonary tuberculosis in Finland: a cohort study.

Authors:  Tuula Vasankari; Pekka Holmström; Jukka Ollgren; Kari Liippo; Petri Ruutu
Journal:  BMC Public Health       Date:  2010-07-06       Impact factor: 3.295

Review 9.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069

10.  Persistent high incidence of tuberculosis in immigrants in a low-incidence country.

Authors:  Troels Lillebaek; Ase B Andersen; Asger Dirksen; Else Smith; Lene T Skovgaard; Axel Kok-Jensen
Journal:  Emerg Infect Dis       Date:  2002-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.